A randomised cross-over study of effects of vasodilator treatment on left ventricular mass and volume in patients with chronic aortic regurgitation
National Heart Foundation of NZ
25 participants
Oct 1, 2010
Interventional
Conditions
Summary
The aim of this study is to determine whether vasodilators, a type of blood pressure treatment, will improve heart function in persons with leaking of the aortic valve. Our hypothesis is that lowering blood pressure will reduce the work of the heart, and over time the volume and thickness of the muscle of the heart's main pumping chamber will improve.
Eligibility
Inclusion Criteria1
- Moderate or severe asymptomatic aortic regurgitation
Exclusion Criteria4
- current indication for aortic valve replacement
- other clinically significant cardiac disease
- contraindication to cardiac magnetic resonance imaging
- atrial fibrillation
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Open label oral vasodilator treatment with dose adjusted according to blood pressure and patient tolerance. Perendopril (2 to 8mg daily) candesartan (4 to 32 mg daily)and/or amlodipine (2.5 to 10mg daily). Either one or a combination of these treatments will be administered to achieve a reduction in blood pressure and adjusted according to tolerance and blood pressure, and continued for one year
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12610000753055